Skip to content

US · ARDX · BIOTECHNOLOGY

Ardelyx, Inc. (ARDX) intrinsic value and stock valuation

$2.99as of 2026-11-21 · Mkt cap 1.21B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ardelyx, Inc. DCF and intrinsic value

InvestorsCraft values ARDX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ARDX’s statements →

Ardelyx, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 ardelyx.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$407.3M+121.9% 5y CAGRd
20122025
Net income
-$-61.6M
20122025
Free cash flow
-$-43.98M
20122025
Total equity
$167M+5.8% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$407.3M$333.6M$124.5M$52.2M$10.1M
Operating income-$-40.98M-$-27.95M-$-63.28M-$-63.76M-$-154.35M
Net income-$-61.6M-$-39.14M-$-66.07M-$-67.21M-$-158.16M
EPSd-$-255.57K-$-166.39K-$-301.24K-$-423.53K-$-1.52M
Operating cash flow-$-42.48M-$-44.81M-$-89.72M-$-70.04M-$-152.55M
Capital expenditure-$-1.49M-$-1.01M-$-340K-$-60K-$-1.87M
Free cash flow-$-43.98M-$-45.82M-$-90.06M-$-70.1M-$-154.42M
Total assets$501.6M$435.8M$297.6M$190.1M$149.9M
Total debt$211.6M$153.4M$56M$36.5M$45.5M
Net debt$143.6M$88.5M$34.5M-$-59.68M-$-26.92M
Total equity$167M$173.3M$166.8M$98.3M$82.6M
Cash and short-term investments$264.7M$250.1M$184.3M$123.9M$116.7M
Income statement
20252024202320222021
Revenue$407.3M$333.6M$124.5M$52.2M$10.1M
Cost of revenue$42.6M$50.6M$17.8M$4.12M$1M
Gross profit$364.7M$283.1M$106.7M$48M$9.1M
Research and development expenses$68.5M$52.3M$35.5M$35.2M$91.1M
Selling, general and administrative expenses$337.2M$258.7M$134.4M$76.6M$72.3M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$405.7M$311M$169.9M$111.8M$163.4M
Cost and expenses$448.3M$361.6M$187.7M$115.9M$164.4M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$28.4M$20.1M$8.87M$5.07M$4.5M
Depreciation and amortization$3.06M$2.06M$1.29M$1.14M$2.81M
Ebitda-$-29.17M-$-16.71M-$-55.35M-$-60.98M-$-150.85M
Operating income-$-40.98M-$-27.95M-$-63.28M-$-63.76M-$-154.35M
Total other income/expenses, net-$-19.65M-$-10.92M-$-2.24M-$-3.44M-$-3.81M
Income before tax-$-60.63M-$-38.87M-$-65.52M-$-67.2M-$-158.16M
Income tax expense$970K$270K$550K$10K$0.00
Net income-$-61.6M-$-39.14M-$-66.07M-$-67.21M-$-158.16M
Weighted average shares outstanding$241M$235.2M$219.3M$158.7M$104.2M
Weighted average diluted shares outstanding$241M$235.2M$219.3M$158.7M$104.2M
Balance sheet
20252024202320222021
Cash and short-term investments$264.7M$250.1M$184.3M$123.9M$116.7M
Net receivables$71.9M$57.7M$22M$7.73M$500K
Inventory$17.7M$21.2M$12.5M$3.28M$0.00
Total current assets$382.3M$356.5M$246.1M$153.6M$133.7M
Property, plant and equipment, net$6.98M$3.88M$6.6M$10.5M$15.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$119.3M$79.3M$51.5M$36.5M$16.3M
Total assets$501.6M$435.8M$297.6M$190.1M$149.9M
Accounts payable$19.2M$16M$11.1M$10.9M$4.28M
Short-term debt$1.48M$1.56M$4.43M$30.6M$35.8M
Deferred revenue$1.21M$10.7M$7.18M$4.21M$0.00
Total current liabilities$88.6M$77.8M$50.4M$65.6M$52.8M
Long-term debt$210.1M$151.9M$51.6M$5.86M$9.75M
Deferred revenue, non-current$39.6M$7.23M$8.64M$9.03M$0.00
Total non-current liabilities$246.1M$184.6M$80.4M$26.1M$14.5M
Capital lease obligations$3.64M$2.58M$6.16M$9.75M$13.2M
Total liabilities$334.7M$262.5M$130.8M$91.7M$67.3M
Common stock$20K$20K$20K$20K$10K
Retained earnings-$-946.94M-$-885.34M-$-846.2M-$-780.14M-$-712.93M
Accumulated other comprehensive income (loss)$200K$60K$220K-$-50K-$-10K
Total equity$167M$173.3M$166.8M$98.3M$82.6M
Total investments$196.7M$185.2M$162.8M$27.8M$44.3M
Total debt$211.6M$153.4M$56M$36.5M$45.5M
Net debt$143.6M$88.5M$34.5M-$-59.68M-$-26.92M
Cash flow statement
20252024202320222021
Net income-$-61.6M-$-39.14M-$-66.07M-$-67.21M-$-158.16M
Depreciation and amortization$3.06M$2.06M$1.29M$1.14M$1.44M
Stock-based compensation$49M$37.4M$13.5M$10.8M$12M
Change in working capital-$-31.35M-$-49.17M-$-43.39M-$-19.57M-$-11.92M
Accounts receivable-$-14.14M-$-35.67M-$-14.3M-$-7.23M-$-500K
Inventory-$-31.92M-$-41.7M-$-21.14M-$-28.35M-$-10.37M
Accounts payable$3.23M$4.86M$280K$6.58M-$-1.35M
Net cash provided by operating activities-$-42.48M-$-44.81M-$-89.72M-$-70.04M-$-152.55M
Investments in property, plant and equipment-$-1.49M-$-1.01M-$-340K-$-60K-$-1.87M
Acquisitions, net$0.00$0.00$0.00$0.00-$-52.81M
Net cash used for investing activities-$-8.96M-$-18.32M-$-131.25M$18.4M$51M
Common stock issued$5.84M$8.14M$119.2M$71.6M$101.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$54.5M$106.6M$146.3M$75.3M$83M
Net change in cash$3.07M$43.5M-$-74.67M$23.7M-$-18.6M
Cash at end of period$68M$64.9M$21.5M$96.1M$72.4M
Operating cash flow-$-42.48M-$-44.81M-$-89.72M-$-70.04M-$-152.55M
Capital expenditure-$-1.49M-$-1.01M-$-340K-$-60K-$-1.87M
Free cash flow-$-43.98M-$-45.82M-$-90.06M-$-70.1M-$-154.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ardelyx, Inc.

        Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.

        CEO
        Michael G. Raab
        Employees
        489
        Beta
        0.73

        Explore

        Frequently asked questions

        What is the intrinsic value of Ardelyx, Inc. (ARDX)?

        Ardelyx, Inc. (ARDX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ARDX undervalued?

        ARDX trades at a price of $2.99 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.